Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
IntegraGen
company
About
IntegraGen is a biotechnology company developing molecular markers for central nervous system and metabolic diseases.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- €8M
- Industries
- Biotechnology,Genetics,Health Care,Therapeutics
- Founded date
- Jan 1, 2000
- Number Of Employee
- 11 - 50
- Operating Status
- Active
IntegraGen is a French biotech company based on the Genopole life science park in Evry, near Paris. It leverages its unique intellectual property, research expertise and privileged access to sample libraries to develop molecular markers for central nervous system and metabolic diseases. IntegraGen notably uses its proprietary technology platforms to provide genomics services to the pharmaceutical industry, biotech firms and other research providers.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
€8M
IntegraGen has raised a total of
€8M
in funding over 2 rounds. Their latest funding was raised on
Nov 17, 2005 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 17, 2005 | Series B | €8M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
IntegraGen is funded by 1 investors.
Bioam Gestion
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Bioam Gestion
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
